4300 Hacienda Drive
Roche Molecular Solutions, one of the global business areas within Roche Diagnostics, brings together the diagnostic power of molecular, tissue and sequencing technologies.
With the goal of revolutionizing diagnostic decisions through integrated solutions, Roche Molecular Solutions brings together the latest technologies withinmolecular diagnostics (polymerase chain reaction or PCR-based testing), tissue diagnostics (tissue biopsy testing) and sequencing solutions (next-generation DNA and RNA sequence-based testing) to advance the standard of care for everyone.
Roche is the world leader in molecular and tissue diagnostics, and one of the leaders in clinical sequencing. As the innovation engine for Roche Diagnostics,Roche Molecular Solutions is translating cutting-edge science and innovation into clinical practice.
Visit our Career Blogs to see what our employees have to say about their life at Roche!
188 articles with Roche
For its 2019 list of the top 50 most innovative companies, Fast Company selected 10 from the biotech industry that are having a significant impact on the treatment of patients. The first five are highlighted.
Alexander (Sasha) Opotowsky, associate professor at Harvard Medical School and a cardiologist at Boston Children’s Hospital and Brigham and Women’s Hospital took time out to speak with BioSpace about advances in heart health, congenital heart disease (CHD), biopharma, and the Adult Congenital Hea...
According to WARN notices, the two companies will slash a total of 106 jobs starting in March.
Chugai Pharmaceutical Co., Ltd. announced that Roche has received notification that the EU Committee for Medicinal Products for Human Use adopted a positive opinion for Hemlibra®
Roche announced that it was discontinuing two of its Alzheimer’s Phase III trials, CREAD I and 2, after a pre-planned interim analysis.
First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease
First of 4+ Ionis programs expected to advance to pivotal studies this year
Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer
Basilea Pharmaceutica Ltd. announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®), in patients with urothelial cancer. Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study in mid-2019.
Roche launches uPath enterprise software with improved speed, performance and usability for digital pathology
Personalized workflow software allows pathologists to move seamlessly between a variety of stains in a single view, which is not possible with a standard microscope
C4 Therapeutics Announces Transformation of Strategic Collaboration to Discover and Develop Degrader-Based Medicines with Roche
C4 Therapeutics announced the transformation of its ongoing research and development partnership with Roche focusing on new cancer treatments based on C4T’s targeted protein degradation technology
Alcyone Lifesciences Announces Broad Strategic Collaboration with Roche in the Field of Intrathecal Therapies
Collaboration leverages strengths to advance the progress of intrathecal therapies to treat severe neurological conditions
Roche to develop companion diagnostic test to help identify patients eligible for anti-PD-1 therapy based on biomarker expression, not location, of solid tumors
Roche collaborates with Merck to develop companion diagnostic for use with Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in advanced solid tumors with mismatch repair deficiency (dMMR)
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Susan G. Komen® Hails Findings from KATHERINE Trial Showing New Treatment Option That Reduces Breast Cancer Recurrence/Death Risk
Findings provide hope for long-term survival for HER2+ breast cancer patients
Collaboration includes the initial program utilizing Icagen's Drug Discovery Platform.
Many of these directors do not publicly disclose their affiliation with the pharma companies in their nonprofit biographies, report shows.
Roche subsidiary Genentech snaps up Jecure and its portfolio of preclinical NLRP3 inhibitors aimed at serious inflammatory diseases.
The VENTANA pan-TRK (EPR17341) Assay is the first assay of its type to detect tropomyosin receptor kinase (TRK) with anticipated use across multiple solid tumor types
Daiichi Sankyo Company, Limited announced today that it has entered into an agreement with Roche to collaborate on the development of a new HER2 low companion diagnostic test.
Shanghai Roche Pharmaceuticals Ltd. and Ascletis BioScience Co., Ltd. jointly announce that starting from 1st Dec 2018, Ascletis and Roche will expand their partnership in viral Hepatitis.
Tesaro, located in Waltham, Mass., is rumored to be up for sale. The rumors caused shares to rocket as much as 39 percent on Friday, but it’s not the first time rumors have floated that the company might be on the auction block.